Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.
Choose from the criteria below to find an activity that fits you best.
Three dates available!
Tuesday, August 27, 2019, 11:00 AM - 12:00 PM CT - Register to attend August 27
Thursday, September 5, 2019, 2:00 PM - 3:00 PM CT - Register to attend September 5
Tuesday, September 17, 2019, 12:00 PM - 1:00 PM CT - Register to attend September 17
|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
The World Health Organization (WHO) has listed both vaccine hesitancy and a global
influenza pandemic as two of the top ten threats in 2019. Overall rates of vaccination
in the United States falls far below recommended levels, with only about 43% of adults
receiving a yearly influenza vaccine. Fortunately, there is evidence that utilizing
pharmacists as immunizers has had a positive effect on immunization rates, increasing
access to immunization for the general public. However, given the poor vaccination
rates among US adults, there is still a great deal of work to be done by pharmacists
and other healthcare professionals in improving vaccine uptake.
This activity will provide pharmacists with education on the burden of influenza, expert guideline updates for treatment in high-risk populations and timing of antiviral initiation, vaccine administration for the prevention of influenza, available therapies, and approaches pharmacists can take to increase uptake of vaccine prophylaxis. Interactive questions will serve to demonstrate and reinforce the latest influenza developments and how to overcome common challenges to adherence or vaccine hesitancy.
The target audience for this activity includes pharmacists. At the completion of this activity, the participant will be able to:
Mary S. Hayney, PharmD, MPH
Professor of Pharmacy (CHS)
University of Wisconsin School of Pharmacy
This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-284-L01-P has been assigned to this live knowledge-based activity (initial release date 8-27-2019). This activity is approved for 1.0 contact hours (0.1 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Faculty conflict of interest will be announced prior to the start of the activity.
This activity is supported by an educational grant from Genentech, Inc.
Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.